2016
DOI: 10.2217/cer-2016-0027
|View full text |Cite
|
Sign up to set email alerts
|

Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System

Abstract: Aim: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil. This open prospective cohort study evaluated their effectiveness and safety among RA patients in the Brazilian Public Health System given their costs. Methods: The Clinical Disease Activity Index was primarily used to assess their effectiveness after 6 and 12 months of follow-up. The Health Assessment Questionnaire and EuroQol-5D were also u… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
12
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
9

Relationship

5
4

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 38 publications
(34 reference statements)
1
12
0
Order By: Relevance
“…Adalimumab was the most requested anti-TNF agent, followed by etanercept. This anti-TNF utilization profile is consistent with the literature, where adalimumab has been the medication most commonly utilized in the treatment of PsA and other rheumatic diseases in Brazil [33][34][35]. This could be partially explained as adalimumab presents additional treatment indications, such as uveitis, and this is a characteristic that is not shared with etanercept.…”
Section: Discussionsupporting
confidence: 89%
“…Adalimumab was the most requested anti-TNF agent, followed by etanercept. This anti-TNF utilization profile is consistent with the literature, where adalimumab has been the medication most commonly utilized in the treatment of PsA and other rheumatic diseases in Brazil [33][34][35]. This could be partially explained as adalimumab presents additional treatment indications, such as uveitis, and this is a characteristic that is not shared with etanercept.…”
Section: Discussionsupporting
confidence: 89%
“…These examples of MEAs can be seen as part of a general approach within healthcare systems to monitor the effectiveness, safety and value of new medicines where possible especially where there are concerns initially with their effectiveness, safety and value in routine clinical care (144,(147)(148)(149)(150)(151)(152)(153)(154)(155)(156) . In addition, be part of a general move away from a policy model of one-time evaluation regarding the incorporation of a new technology into health care systems towards a model of multiple evaluations of new health technologies over time.…”
Section: Challenges and Benefits From Measmentioning
confidence: 99%
“…In this review, judicialized medicines for the treatment of chronic diseases, autoimmune, and rare genetic diseases represented the greatest impact on the budget of public health policies 24,26,30,33,41,42,45,46,54,[80][81][82] . Although many drugs are well tolerated and achieve goals of remission, low activity or control of these diseases, the main causes of the evolution of expenditures are the preferences of prescribers and the success of judicial demands, without considering the cost-effectiveness of these medicines 75,[83][84][85] . The articles usually only mentioned expenditures and growth trends, suggesting the need for greater financial control of health policies [78][79][80] .…”
Section: Discussionmentioning
confidence: 99%